JP2021098728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021098728A5 JP2021098728A5 JP2021037000A JP2021037000A JP2021098728A5 JP 2021098728 A5 JP2021098728 A5 JP 2021098728A5 JP 2021037000 A JP2021037000 A JP 2021037000A JP 2021037000 A JP2021037000 A JP 2021037000A JP 2021098728 A5 JP2021098728 A5 JP 2021098728A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- orally administered
- acceptable excipient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023032872A JP2023060145A (ja) | 2018-05-14 | 2023-03-03 | Mcl-1阻害剤 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862671306P | 2018-05-14 | 2018-05-14 | |
US62/671,306 | 2018-05-14 | ||
US201862749918P | 2018-10-24 | 2018-10-24 | |
US62/749,918 | 2018-10-24 | ||
JP2020564228A JP6899975B2 (ja) | 2018-05-14 | 2019-05-13 | Mcl−1阻害剤 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020564228A Division JP6899975B2 (ja) | 2018-05-14 | 2019-05-13 | Mcl−1阻害剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023032872A Division JP2023060145A (ja) | 2018-05-14 | 2023-03-03 | Mcl-1阻害剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021098728A JP2021098728A (ja) | 2021-07-01 |
JP2021098728A5 true JP2021098728A5 (US20070167479A1-20070719-C00034.png) | 2022-10-12 |
JP7240431B2 JP7240431B2 (ja) | 2023-03-15 |
Family
ID=66770559
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020564228A Active JP6899975B2 (ja) | 2018-05-14 | 2019-05-13 | Mcl−1阻害剤 |
JP2021037000A Active JP7240431B2 (ja) | 2018-05-14 | 2021-03-09 | Mcl-1阻害剤 |
JP2023032872A Pending JP2023060145A (ja) | 2018-05-14 | 2023-03-03 | Mcl-1阻害剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020564228A Active JP6899975B2 (ja) | 2018-05-14 | 2019-05-13 | Mcl−1阻害剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023032872A Pending JP2023060145A (ja) | 2018-05-14 | 2023-03-03 | Mcl-1阻害剤 |
Country Status (29)
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20200544A (es) | 2018-05-14 | 2021-02-11 | Gilead Sciences Inc | Inhibidores de mcl-1 |
MX2022000390A (es) | 2019-07-09 | 2022-02-10 | Janssen Pharmaceutica Nv | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. |
CN118178645A (zh) | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
JP2022552748A (ja) | 2019-10-31 | 2022-12-19 | フォーティ セブン, インコーポレイテッド | 抗cd47及び抗cd20による血液癌の治療 |
TWI778443B (zh) * | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
CN114787139A (zh) * | 2019-11-26 | 2022-07-22 | 吉利德科学公司 | 用于制备mcl1抑制剂的方法和中间体 |
PE20230376A1 (es) | 2019-12-24 | 2023-03-06 | Carna Biosciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
US20230212191A1 (en) * | 2020-04-16 | 2023-07-06 | Prelude Therapeutics, Incorporated | Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein |
US20230219906A1 (en) * | 2020-06-10 | 2023-07-13 | Janssen Pharmaceutica Nv | Macrocyclic-2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1 |
KR20230107848A (ko) * | 2020-11-19 | 2023-07-18 | 길리애드 사이언시즈, 인코포레이티드 | 거대고리형 mcl1 저해제를 제조하기 위한 방법 및 중간체 |
AU2021404501A1 (en) | 2020-12-17 | 2023-08-03 | Janssen Pharmaceutica Nv | Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1 |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
CN117295749A (zh) | 2021-04-26 | 2023-12-26 | 詹森药业有限公司 | 作为mcl-1抑制剂的大环2-烯丙基四氢呋喃 |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
KR20240019283A (ko) | 2021-06-11 | 2024-02-14 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 저해제와 항암제의 병용 |
EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3237011A1 (en) | 2021-11-16 | 2023-05-25 | Soufyan JERHAOUI | Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1 |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
WO2023215404A1 (en) | 2022-05-04 | 2023-11-09 | Gilead Sciences, Inc. | Salts and polymorphs of certain mcl-1 inhibitors |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
ES2605792T3 (es) | 2004-05-13 | 2017-03-16 | Icos Corporation | Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana |
US20090142345A1 (en) | 2005-03-15 | 2009-06-04 | Takeda Pharmaceutical Company Limited | Prophylactic/therapeutic agent for cancer |
EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
SI1907424T1 (sl) | 2005-07-01 | 2015-12-31 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1) |
MX2009009792A (es) | 2007-03-12 | 2009-09-23 | Cytopia Res Pty Ltd | Compuestos de fenil amino pirimidina y usos de los mismos. |
HUE025283T2 (en) | 2007-08-02 | 2016-03-29 | Gilead Biologics Inc | LOX and LOX2 inhibitors and their use |
PT2310509E (pt) | 2008-07-21 | 2015-05-19 | Apogenix Gmbh | Moléculas de tnfsf em cadeia simples |
US8652843B2 (en) | 2008-08-12 | 2014-02-18 | Oncomed Pharmaceuticals, Inc. | DDR1-binding agents and methods of use thereof |
US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
AU2011212830B2 (en) | 2010-02-04 | 2014-05-22 | Gilead Biologics, Inc. | Antibodies that bind to lysyl oxidase-like 2 (LOXL2) and methods of use therefor |
US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
JP5878538B2 (ja) | 2010-08-27 | 2016-03-08 | ギリアド バイオロジクス, インク.Gilead Biologics, Inc. | マトリクスメタロプロティナーゼ9に対する抗体 |
KR20230133410A (ko) | 2010-12-09 | 2023-09-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도 |
TWI567061B (zh) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
EP2749572A4 (en) | 2011-08-23 | 2015-04-01 | Chugai Pharmaceutical Co Ltd | NEW ANTI-DDR1 ANTIBODY WITH ANTITUMORACTIVITY |
GB201115529D0 (en) | 2011-09-08 | 2011-10-26 | Imp Innovations Ltd | Antibodies, uses and methods |
WO2013052699A2 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
WO2013116562A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Calistoga Llc | Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile |
TW201427995A (zh) | 2012-09-24 | 2014-07-16 | Gilead Sciences Inc | 抗ddr1抗體 |
TW201441216A (zh) | 2012-12-21 | 2014-11-01 | Gilead Calistoga Llc | 肌醇磷酯3-激酶的抑制劑 |
AU2013364070B2 (en) | 2012-12-21 | 2016-10-27 | Gilead Calistoga Llc | Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors |
TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
MX347988B (es) | 2013-06-14 | 2017-05-19 | Gilead Sciences Inc | Inhibidores de fosfatidilinositol 3-cinasa. |
MY176803A (en) | 2013-07-30 | 2020-08-21 | Gilead Connecticut Inc | Polymorph of syk inhibitors |
TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
CN106456602B (zh) * | 2014-03-27 | 2020-11-24 | 范德比尔特大学 | 取代的吲哚mcl-1抑制剂 |
EP3943507A1 (en) | 2014-04-10 | 2022-01-26 | Seattle Children's Hospital, dba Seattle Children's Research Institute | Drug related transgene expression |
TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
JO3474B1 (ar) * | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
ES2881195T3 (es) | 2014-09-26 | 2021-11-29 | Gilead Sciences Inc | Derivados de aminotriazina útiles como compuestos inhibidores de quinasas que se unen a TANK |
KR20170087514A (ko) | 2014-12-03 | 2017-07-28 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 방법 및 조성물 |
WO2016100236A2 (en) | 2014-12-15 | 2016-06-23 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
ES2761824T3 (es) | 2015-05-15 | 2020-05-21 | Gilead Sciences Inc | Compuestos de carboximidamida de benzimidazol y imidazopiridina que tienen actividad como inhibidores de indoleamina 2,3-dioxigenasa |
US20180161368A1 (en) | 2015-05-29 | 2018-06-14 | Juno Therapeutics, Inc. | Composition and methods for regulating inhibitory interactions in genetically engineered cells |
US20180258149A1 (en) | 2015-09-17 | 2018-09-13 | Novartis Ag | Car t cell therapies with enhanced efficacy |
US11306107B2 (en) * | 2016-02-25 | 2022-04-19 | Amgen Inc. | Compounds that inhibit MCL-1 protein |
JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Mcl−1タンパク質を阻害する化合物 |
EP3668878A1 (en) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
MA50033A (fr) | 2017-08-29 | 2020-07-08 | Amgen Inc | Composés macrocycliques permettant d'inhiber la protéine mcl-1 |
KR20200074965A (ko) | 2017-10-19 | 2020-06-25 | 암젠 인크 | 벤즈이미다졸 유도체 및 이의 용도 |
EP3762393B1 (en) | 2018-03-05 | 2023-01-11 | Amgen Inc. | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere mcl-1 protein antagonists |
CR20200544A (es) | 2018-05-14 | 2021-02-11 | Gilead Sciences Inc | Inhibidores de mcl-1 |
WO2019222269A1 (en) | 2018-05-14 | 2019-11-21 | Reata Pharmaceuticals, Inc. | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway |
TW201946906A (zh) | 2018-05-15 | 2019-12-16 | 美商阿拜德生物製藥公司 | Magl抑制劑 |
MX2021000881A (es) | 2018-07-24 | 2021-06-08 | Epizyme Inc | Compuestos de piridin-2-ona utiles como antagonistas de smarca2. |
CA3118919A1 (en) | 2018-11-09 | 2020-05-14 | Prelude Therapeutics, Incorporated | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein |
TWI745836B (zh) | 2019-01-18 | 2021-11-11 | 大陸商蘇州亞盛藥業有限公司 | 作為mcl-1抑製劑的大螺環醚 |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
CN114787139A (zh) | 2019-11-26 | 2022-07-22 | 吉利德科学公司 | 用于制备mcl1抑制剂的方法和中间体 |
JP2021161114A (ja) | 2020-03-31 | 2021-10-11 | アムジエン・インコーポレーテツド | Mcl−1化合物のメチル化 |
TWI827924B (zh) | 2020-05-06 | 2024-01-01 | 美商安進公司 | 大環Mcl-1抑制劑中間體的閉環合成 |
CA3181214A1 (en) | 2020-05-06 | 2021-11-11 | Amgen Inc. | Synthesis of vinylic protected alcohol intermediates |
US20230219906A1 (en) | 2020-06-10 | 2023-07-13 | Janssen Pharmaceutica Nv | Macrocyclic-2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1 |
US20230250109A1 (en) | 2020-07-08 | 2023-08-10 | Janssen Pharmaceutica Nv | Macrocyclic ether containing indole derivatives as inhibitors of mcl-1 |
KR20230107848A (ko) | 2020-11-19 | 2023-07-18 | 길리애드 사이언시즈, 인코포레이티드 | 거대고리형 mcl1 저해제를 제조하기 위한 방법 및 중간체 |
-
2019
- 2019-05-13 CR CR20200544A patent/CR20200544A/es unknown
- 2019-05-13 CN CN201980032695.2A patent/CN112118845B/zh active Active
- 2019-05-13 LT LTEPPCT/US2019/032053T patent/LT3793565T/lt unknown
- 2019-05-13 CN CN202310897123.9A patent/CN117304130A/zh active Pending
- 2019-05-13 JP JP2020564228A patent/JP6899975B2/ja active Active
- 2019-05-13 US US16/410,457 patent/US10703733B2/en active Active
- 2019-05-13 AU AU2019269391A patent/AU2019269391B2/en active Active
- 2019-05-13 UA UAA202006695A patent/UA125163C2/uk unknown
- 2019-05-13 PT PT197287931T patent/PT3793565T/pt unknown
- 2019-05-13 BR BR112020021648-8A patent/BR112020021648A2/pt unknown
- 2019-05-13 PL PL19728793T patent/PL3793565T3/pl unknown
- 2019-05-13 IL IL291430A patent/IL291430B2/en unknown
- 2019-05-13 KR KR1020207035485A patent/KR102551319B1/ko active IP Right Grant
- 2019-05-13 PE PE2020001829A patent/PE20210004A1/es unknown
- 2019-05-13 EP EP19728793.1A patent/EP3793565B1/en active Active
- 2019-05-13 KR KR1020247015778A patent/KR20240074001A/ko active Search and Examination
- 2019-05-13 ES ES19728793T patent/ES2907923T3/es active Active
- 2019-05-13 EP EP21218221.6A patent/EP4029868A1/en active Pending
- 2019-05-13 SG SG11202010964VA patent/SG11202010964VA/en unknown
- 2019-05-13 HR HRP20220215TT patent/HRP20220215T1/hr unknown
- 2019-05-13 KR KR1020237022152A patent/KR102666717B1/ko active IP Right Grant
- 2019-05-13 CA CA3099152A patent/CA3099152C/en active Active
- 2019-05-13 DK DK19728793.1T patent/DK3793565T3/da active
- 2019-05-13 SI SI201930181T patent/SI3793565T1/sl unknown
- 2019-05-13 MX MX2020012137A patent/MX2020012137A/es unknown
- 2019-05-13 HU HUE19728793A patent/HUE057852T2/hu unknown
- 2019-05-13 WO PCT/US2019/032053 patent/WO2019222112A1/en unknown
- 2019-05-14 TW TW108116508A patent/TWI719478B/zh active
- 2019-05-14 TW TW110107128A patent/TWI813957B/zh active
-
2020
- 2020-04-23 US US16/857,021 patent/US10988451B2/en active Active
- 2020-10-27 IL IL278336A patent/IL278336B/en unknown
- 2020-11-03 PH PH12020551881A patent/PH12020551881A1/en unknown
- 2020-11-10 CO CONC2020/0014009A patent/CO2020014009A2/es unknown
- 2020-11-10 CL CL2020002919A patent/CL2020002919A1/es unknown
- 2020-11-10 ZA ZA2020/07007A patent/ZA202007007B/en unknown
-
2021
- 2021-02-09 US US17/171,201 patent/US11643400B2/en active Active
- 2021-03-09 JP JP2021037000A patent/JP7240431B2/ja active Active
- 2021-05-25 AU AU2021203373A patent/AU2021203373B2/en active Active
-
2022
- 2022-03-16 CY CY20221100208T patent/CY1125065T1/el unknown
-
2023
- 2023-03-03 JP JP2023032872A patent/JP2023060145A/ja active Pending
- 2023-03-09 US US18/181,336 patent/US20230312490A1/en active Pending
- 2023-11-24 AU AU2023270332A patent/AU2023270332A1/en active Pending